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Abstract 
BACKGROUND: Long-term risk of post-discharge mortality associated with acute 
coronary syndrome (ACS) remains a concern. The development of a model to 
reliably estimate 2-year mortality risk from hospital discharge post-ACS will help 
guide treatment strategies. 
METHODS: EPICOR (long-tErm follow uP of antithrombotic management patterns In 
acute CORonary syndrome patients, NCT01171404) and EPICOR Asia (EPICOR 
Asia, NCT01361386) are prospective observational studies of 23,489 patients 
hospitalized for an ACS event, who survived to discharge and were then followed up 
for 2 years. Patients were enrolled from 28 countries across Europe, Latin America, 
and Asia. Risk scoring for 2-year all-cause mortality risk was developed using 
identified predictive variables and forward stepwise Cox regression. Goodness-of-fit 
and discriminatory power was estimated. 
RESULTS: 5.5% of patients died within 2 years of discharge. We identified 17 
independent mortality predictors: age, low ejection fraction, no coronary 
revascularisation/thrombolysis, elevated serum creatinine, poor EQ-5D score, low 
haemoglobin, previous cardiac or chronic obstructive pulmonary disease, elevated 
blood glucose, on diuretics or an aldosterone inhibitor at discharge, male sex, low 
educational level, in-hospital cardiac complications, low BMI, STEMI diagnosis, and 
Killip class. Geographic variation in mortality risk was seen following adjustment for 
other predictive variables. The developed risk-scoring system provided excellent 
discrimination (c-statistic=0.80, 95% CI=0.79‒0.82) with a steep gradient in 2-year 
mortality risk: >25% (top decile) vs. ~1% (bottom quintile). A simplified risk model 
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with 11 predictors gave only slightly weaker discrimination (c-statistic=0.79, 95% CI 
=0.78 to 0.81). 
CONCLUSIONS: This risk score for 2-year post-discharge mortality in ACS patients 
(www.acsrisk.org) can facilitate identification of high-risk patients and help guide 
tailored secondary prevention measures. 
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Introduction 
There is still much variability in long-term prognosis for patients who present with an 
acute coronary syndrome (ACS) and survive to discharge from hospital.1 After 
leaving hospital, risk from further ischemic events and death is compounded by high 
variability in secondary prevention measures both at-discharge and subsequently.2-4 
Hospital discharge therefore represents a crucial point for the assessment of 
individual patient risk and the adoption of appropriate management strategies, 
including advice to the patient.5, 6 The ability to identify those patients with poor 
prognosis on leaving hospital could potentially guide optimal patient management. 
There are several reports on the use of risk scoring methods in ACS with a 
few large-scale observational studies having identified predictors of mortality 
following an ACS event.7, 8 Most notable are the Global Registry of Acute Coronary 
Events (GRACE) risk scores,9 although these focus mainly on risk from time of 
hospital admission and, as such, represent a different scenario. Additionally, Eagle 
et al10 provide a risk model for post-discharge mortality, albeit with follow-up of only 6 
months. We previously examined 10,567 patients with ACS from Europe and Latin 
America in the EPICOR (long-tErm follow uP of antithrombotic management patterns 
In acute CORonary syndrome patients) study11 and established a reliable risk-
scoring tool for evaluating 1-year post-discharge mortality risk.12  
Data are now available up to 2-years post-discharge in a larger patient 
population including both the EPICOR and the EPICOR Asia (n=12,922 patients)13 
studies. Assessment of risk based on this increased sample size will provide 
increased predictive reliability and generalizability to different geographic regions 
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and healthcare systems. The aim is to explore relationships between patient 
demographics, medical history and management from data collected during 
admission, hospitalization, and at discharge, and subsequent 2-year mortality, 
thereby facilitating the development of a reliable and user-friendly risk-scoring 
system for individual patient 2-year survival. 
6 
 
Methods 
EPICOR and EPICOR Asia are prospective, international cohort studies of 
unselected populations comprising consecutive patients hospitalized for an ACS 
event (ST-segment elevation myocardial infarction [STEMI], and non-ST-segment 
elevation myocardial infarction or unstable angina [NSTE-ACS]) either within 24 h 
(EPICOR) or 48 h (EPICOR Asia) of symptom onset, and who survived to hospital 
discharge. 
Follow-up data were available for 23,489 patients enroled from 774 hospitals 
in 28 countries (EPICOR, 10,567 patients from 555 hospitals in 20 countries across 
Europe and Latin America; EPICOR Asia, 12,922 patients from 219 hospitals across 
8 countries and regions in Asia). The primary aim of these studies was to describe 
the frequency of different short- and long-term anti-thrombotic management patterns 
(AMPs) for patients with an ACS, both during hospitalization for the index event and 
after hospital discharge (up to 2 years) in a wide range of hospitals and countries. In 
addition, relationships between AMPs used and clinical outcomes were evaluated. 
The protocol and case record forms of both EPICOR and EPICOR Asia are almost 
identical and detailed accounts of the methodologies of both studies are described 
elsewhere.11, 13-15 In brief, the National Coordinator in each country was responsible 
for site selection and, based on comprehensive lists of hospitals, defined the 
proportion of patients treated at hospitals with and without invasive cardiac 
intervention facilities, thus ensuring a fair representation of real-life practice at a 
country level. Each participating site completed a questionnaire to provide 
information on key site characteristics and aimed to enrol at least 10 consecutive 
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patients; enroled at the point of hospital discharge. Eligible patients were required to 
provide written informed consent, and agree to be contacted by telephone for regular 
follow-up interviews during the post-discharge phase. All data were collected using 
electronic case report forms, set-up and managed by the AstraZeneca Data 
Management Hub in Sweden. The final protocol for each study was approved by the 
applicable ethics committee from each country, and each was performed in 
accordance with ethical principles consistent with the Declaration of Helsinki 
revision, the International Conference on Harmonization Good Clinical Practice 
guideline, and applicable legislation on non-interventional studies. 
Statistical Methods 
In total, 55 candidate variables were identified as potential predictors based on data 
collected during admission, hospitalization, and at discharge relating to patient 
demographics, medical history and other relevant information (see Appendix Table 
1). Using Cox proportional hazard models with forward stepwise variable selection 
(employing P<.01 as a criterion for variable inclusion) an initial risk model for 2-year 
mortality was developed.  
Further analyses were undertaken to ensure assumptions of the model were 
not violated, for example potential non-linearity of prediction, and the model refined 
accordingly. Additionally, Schoenfeld residuals were used to test the proportional 
hazards assumption of every variable included in the final model and, based on this, 
there was no evidence the assumption was violated for any variable. 
As a result, some continuous predictors were remodelled either with a binary 
cut-off point e.g., for body mass index (BMI) and haemoglobin, or expressed as a 
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linear trend only above a certain threshold e.g., for creatinine and blood glucose. 
Separate risk models for NSTE-ACS and STEMI patients were explored, but showed 
no evidence of interactions. We did not explore potential statistical interactions 
between predictor variables because the large number of such analyses would 
facilitate identification of false positive findings. 
To allow for prognostic variables having some missing data (Table 1) multiple 
imputation was used in the final model to avoid unnecessary loss of observations.16 
For continuous variables, the transformation then imputation method of Von Hippel16 
was used to aid in deriving reliable risk estimates. While most identified predictor 
variables are familiar, one valuable addition is the EuroQoL (EQ-5D) patient 
questionnaire.17 Using the EQ-5D, the patient graded each of five parameters i.e., 
mobility, self-care, ability to perform usual activities, pain/discomfort, and 
anxiety/depression as ‘no problem’ (0 points), ‘moderate’ (1 point), or ‘a severe 
limitation’ (2 points). Avoiding the use of complex weighted schemes, we provide a 
simple overall score (0 to 10 points) to facilitate user-friendly risk prediction. 
The Nam-D'Agostino test18 was used to assess goodness-of-fit in comparing 
observed- vs. model-derived mortality risk. 
The model was internally validated using a bootstrap method, as opposed to 
data-splitting, to estimate the discriminative ability of the model when used on 
external data.19 Use of the bootstrap method has been shown to have comparable 
accuracy to external validation20, 21 and avoided the loss of valid data for the model 
building phase.  
All analyses were performed using Stata 14.0. 
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Results 
The study cohort comprised a total of 23,489 consecutive patients presenting with an 
ACS event who survived to hospital discharge (EPICOR n=10,567; EPICOR Asia 
n=12,922). Mean age was 60.9 years, 24% were female, and 14% had had a prior 
myocardial infarction. Within 2 years following hospital discharge, 5.5% of patients 
(n=1,282) had died. Overall, 13.7% of patients did not achieve 2 years of follow-up, 
but 75% of these had more than 1 year of follow-up. Hence, the total patient years of 
lost follow-up was 6.0%. 
Forward stepwise Cox proportional hazard modelling identified 17 
independent (P<.005) predictors of 2-year mortality risk. Table 1 provides descriptive 
statistics for these 17 predictors overall, and by study and by patient diagnosis 
(STEMI or NSTE-ACS). Of the latter, 55% were declared NSTEMI and 45% unstable 
angina. Table 2 summarizes the multivariable risk model with hazard ratio (HR) and 
95% confidence interval (CI) for each independent predictor. Variables are listed in 
order of statistical strength of prediction based on multiple imputation to overcome 
the issue of missing data. 
The predictors in order of predictive strength were: age, low ejection fraction, 
no coronary revascularisation or thrombolysis performed, raised serum creatinine, 
poor EQ-5D score, low haemoglobin, previous cardiac disease, previous chronic 
obstructive pulmonary disease (COPD) or other chronic lung disease (CLD), and 
raised blood glucose (each P<.00001). Other independent predictors were use of 
either a diuretic or an aldosterone inhibitor at discharge, male sex, low educational 
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level, in-hospital cardiac complications, low BMI, diagnosis of STEMI, and Killip class 
>I.  
When patients diagnosed with STEMI and NSTE-ACS were analyzed 
separately all other predictors showed a similar impact on mortality risk in the two 
risk models (Table 3). Note, in univariate analysis (Table 1), STEMI patients were 
observed to have a lower 2-year mortality than NSTE-ACS patients (5.0% vs 5.9%) 
but the latter had a poorer risk profile in regard to other key predictors such as age. 
Thus, after multivariable adjustment STEMI diagnosis was seen to independently 
contribute to a higher mortality risk (HR 1.22 vs NSTE-ACS). Based on evidence of 
non-linearity in survival prediction, the impact of increased serum creatinine on 
mortality was confined to those with levels ≥1.2 mg/dL. Similarly, cut-off levels ≥140 
mg/dL, <13 g/dL, and <20 kg/m2 were used for blood glucose (linear), haemoglobin 
(categorical), and BMI (categorical), respectively. 
The estimated impact of each predictor on mortality risk from the overall 
model in Table 2 is visually illustrated in Figure 1. Notable increases in mortality risk 
were evident for increasing age, serum creatinine, blood glucose, Killip class, and 
EQ-5D score and reduced risk with increasing haemoglobin, BMI, and improved 
educational level. Further independent predictors of increased mortality risk were; 
low ejection fraction, no coronary revascularisation or thrombolysis during admission, 
in-hospital cardiac complications, previous cardiac disease, previous COPD/other 
CLD, and male sex. In addition, substantial regional differences in 2-year mortality 
risk persisted after adjustment for other predictors. For example, with China as the 
reference country, Northern Europe region, as well as Hong Kong, Singapore, and 
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South Korea combined had the lowest risk (HR 0.72 and 0.60, respectively) while 
Latin America and Eastern Europe had the highest risk (HR 1.44 and 1.24, 
respectively).  
A risk score is calculated for each patient from the risk coefficients of the 
linear predictors for the overall model (Table 2). The 2-year mortality risk for each 
individual is 1 - 0.99842exp(risk score). Figure 2A shows the distribution of individual 
scores for all 23,489 patients along with the relationship between patient risk score 
and the probability of dying within 2 years of discharge. Patients were stratified into 6 
risk groups; groups 1–4 representing the first four quintiles of patients and groups 5 
and 6 representing the top 2 deciles of risk. Figure 2B shows the relationship 
between such risk groups and cumulative mortality over 2 years. From these data 
there is a marked discrimination in mortality across the risk groups. For example, 
comparing extremes, the top decile (group 6) had a 2-year mortality risk greater than 
25% whereas the bottom quintile (group 1) had a 2-year mortality risk around 1%.  
In addition to good discrimination between risk groups, measures of 
goodness-of-fit comparing observed- vs. model-predicted 2-year mortality rates 
based on the Nam-D’Agostino test showed strong similarities between observed and 
predicted mortality (P=.12) i.e., the model provided a good fit of the data across 
mortality risk groups (Figure 2C). In addition, discrimination of the model was found 
to be very good (c-statistic=0.80, 95% CI=0.79‒0.82). The bootstrap validation 
method estimated only a very small degree of bias due to overfitting; overall, 800 
resamples provided an estimated bias of 1.2% (95% CI=0.06%‒3.2%) suggesting 
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Harrell’s c statistic, if the model was used on new, external data, would be 0.798 
(95% CI=0.788‒0.803). 
To facilitate the practical use of our risk model, we have developed a more 
simplified version. This has been achieved by removal of six of the variables which 
had a somewhat lesser impact on patient risk. The variables removed were: on 
diuretics and on aldosterone inhibitor at discharge, education level, in-hospital 
complications, body mass index, and Killip class. The results for this simplified risk 
model (with just 11 predictive variables) are provided in Appendix Table 2 and 
Appendix Figure 1. The model fit remained good, and discriminatory power was only 
slightly reduced (c-statistic=0.79, 95% CI=0.78-0.81). 
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Discussion 
Based on patient data combined from EPICOR and EPICOR Asia,11, 13 two large 
international prospective cohort studies of unselected populations involving more 
than 23,000 patients hospitalized and discharged following an ACS event, we were 
able to identify 17 highly independent predictors of mortality during the 2-year period 
following hospital discharge. The combining of patient data from these large very 
similar studies provided a unique opportunity to reliably quantify long-term individual 
patient risk post discharge based on representative populations across Europe, Latin 
America, and Asia in a variety of healthcare systems. Moreover, the fact that all risk 
predictors identified are conducive to ready quantification/collation in routine clinical 
practice, provided the opportunity for us to create a web-based risk calculator 
(www.acsrisk.org) to facilitate risk prediction for future patients. 
Age, low ejection fraction, lack of use of coronary revascularisation or 
thrombolysis, previous COPD/other CLD, along with raised serum creatinine, raised 
glucose and low haemoglobin levels in blood samples obtained at admission each 
made major contributions to increased mortality risk. The significant effects of 
previous COPD/other CLD, low haemoglobin and raised blood glucose22 confirm that 
non-cardiac conditions do convey a mortality risk in ACS patients.  
The increased risk associated with no coronary revascularisation/thrombolysis 
could mirror risk/benefit analysis and selection strategies against providing such 
intervention in patients with an anticipated poor prognosis post-discharge.23 The 
marked contribution from patient-reported quality of life at discharge, based on a 
simplified scoring system applied to the EQ-5D questionnaire17 indicates how poor 
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functional quality of life at discharge reflects other factors that impact on mortality 
risk in ways not captured by other predictors such as frailty,24 depression or other 
comorbidities. Although in univariate analysis (Table 1) men had a lower 2-year 
mortality risk than women (5.1% vs 6.6%), in the multivariable model accounting for 
other risk factors (e.g., age at presentation), male sex independently predicted a 
32% higher risk. Similarly, STEMI patients overall had a lower 2-year mortality than 
NSTE-ACS patients (5.0% vs 5.9%, respectively) but, after adjustment for other 
predictors, STEMI diagnosis carried an independent 22% higher risk suggesting that 
the poor prognosis of NSTE-ACS was largely driven by older age and comorbidities 
while the consequences of STEMI as such were worse probably driven by significant 
myocardial damage. 
As expected, most patients could be classified as low risk with approximately 
half of patients having a 2-year mortality risk <3%. Only 13% had a 2-year risk >10% 
while 5% had a risk >20%. This is relevant as it may become a clinically useful tool 
to select the patients needing more aggressive secondary prevention strategies.25 
Close agreement was evident between observed and predicted 2-year mortality 
rates across risk groups confirming a good model fit of the data. 
In general, our findings for 2-year mortality post discharge complement those 
reported from EPICOR up to 1-year post discharge.12 The overall mortality rate at 
2-years post-discharge was 5.5% compared with 3.9% after 1-year. We have now 
identified 17 highly predictive variables on 2-year follow-up compared with 12 
previously. The six new predictors are: no coronary revascularisation or thrombolysis 
performed, previous cardiac disease, aldosterone inhibitor use at discharge, 
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education level, diagnosis (STEMI), BMI (<20 kg/m2), and Killip class. Note, a higher 
mortality of underweight patients with coronary artery disease has been previously 
reported.26 One predictor of 1-year mortality, peripheral vascular disease, was no 
longer evident at 2 years.  
There is an extensive literature on the use of risk scores in ACS.8 However, 
for predicting longer-term mortality, the choice is somewhat limited, with the GRACE 
Registry representing the most widely used risk score.9, 27 However, the emphasis of 
GRACE is on prediction from hospital admission, which inherently includes 
substantial in-hospital mortality risk. Our focus is on prognosis from the moment of 
hospital discharge; an appropriate timing when strategies for future patient 
management are determined. 
Analogous to our intent, Eagle et al10 have used the GRACE Registry to develop a 
prediction model for 6-month post-discharge mortality. Based on nine predictor 
variables (age, history of heart failure, history of myocardial infarction, heart rate, 
systolic blood pressure, ST-segment depression, serum creatinine, elevated cardiac 
enzymes, and no in-hospital percutaneous coronary intervention) they achieve good 
discrimination; c=0.81 and 0.75, respectively in development and validation cohorts. 
However, 6 months’ follow-up might be considered too short and a longer-term 
perspective is needed when linking prognosis to patient management. The latest 
GRACE models9 do include post-discharge prediction out to 3 years but have two 
limitations: only data collected at admission are used, and survival data beyond 1 
year is confined to a UK cohort of 1,274 patients.	
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The presence of substantial geographic variations in 2-year mortality risk, 
even after adjustment for the 17 predictors identified in our model, is highly relevant 
given widely acknowledged between-country variability in patient management, and 
the fact this reported risk-scoring model is based on one of the widest ACS cohorts 
ever compiled globally. Further study into the reasons for this variability is warranted. 
Several potential limitations should be noted for the present analysis. There is 
no external validation of the risk model and, being a study on hospital survivors, 
blood pressure and heart rate at admission were not recorded, and some in-hospital 
complications (bleeding, stroke, infection) were not included in the model. It was 
considered a better approach to utilize the entire two cohorts comprising more than 
23,000 patients and 1,292 deaths, and then employ the bootstrap method of internal 
validation. Although STEMI and NSTE-ACS events might be considered sufficiently 
different to require development of two separate risk models, we considered this was 
not necessary given the substantial consistency of risk prediction post-discharge 
across these two event types (Table 3). The possibility exists for inclusion of false 
positive predictor(s) given more than 50 candidate variables were considered 
initially, but the use of P<.01 as an entry criterion should minimise this risk. 
Moreover, as for any observational study, caution must be expressed in 
extrapolating findings to the overall patient population. Since a model with 17 
variables may be considered large for practical use, we have also presented a 
simplified model with just 11 predictive variables. This led to only a very modest loss 
in discriminatory power. It would be of interest to extend our work to predict non-fatal 
ischaemic events and, specifically, cardiovascular death, but this is hampered by 
less reliable data capture compared to the focus on all-cause death. The patient-
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years of loss to follow up (6%) is a limitation but is sufficiently modest to not seriously 
affect the reported findings from this large international cohort study. 
In conclusion, this analysis demonstrates that ACS-related mortality risk up to 
2-years following hospital discharge can be reliably estimated based on 17 highly 
predictive variables, each of which can be readily recorded at hospital discharge. 
Risk discrimination and model fit are good, and use of our easy-to-use risk-scoring 
algorithm (both full and simplified versions are available at www.acsrisk.org) will aid 
identification of those patients with relatively poor prognosis at discharge, and may 
potentially guide tailored secondary prevention measures to improve prognosis in the 
longer term. 
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Table 1. Descriptive statistics for key baseline variables 
 EPICOR EPICOR Asia NSTE-ACS STEMI All Deaths (%) 
Missing 
(%) 
Total 10,567 12,922 11,930 11,559 23,489 5.5  
Age (year) mean (SD) 61.8 (12.3) 60.1 (11.6) 62.8 (11.6) 58.9 (11.9) 60.9 (11.9)  0.004 
Sex       0.0 
Female 2,647 (25.0) 3,065 (23.7) 3,523 (29.5) 2,189 (18.9) 5,712 (24.3) 6.6  
Male 7,920 (75.0) 9,857 (76.3) 8,407 (70.5) 9,370 (81.1) 17,777 (75.7) 5.1  
Region       0.0 
China 0 8,214 (63.6) 4,253 (35.6) 3,961 (34.3) 8,214 (35.0) 4.6  
Hong Kong, Singapore, South Korea 0 975 (7.5) 553 (4.6) 422 (3.7) 975 (4.2) 3.4  
India 0 2,468 (19.1) 986 (8.3) 1,482 (12.8) 2,468 (10.5) 6.7  
Malaysia, Thailand, Vietnam 0 1,265 (9.8) 514 (4.3) 751 (6.5) 1,265 (5.4) 8.1  
Eastern Europe 2,380 (22.5) 0 1,235 (10.4) 1,145 (9.9) 2,380 (10.1) 6.3  
Latin America 2,069 (19.6) 0 1,003 (8.4) 1,066 (9.2) 2,069 (8.8) 8.8  
Northern Europe 3,781 (35.8) 0 2,173 (18.2) 1,608 (13.9) 3,781 (16.1) 3.8  
Southern Europe 2,337 (22.1) 0 1,213 (10.2) 1,124 (9.7) 2,337 (9.9) 5.5  
Education level       22.2 
No formal 477 (6.5) 1,048 (9.6) 798 (8.7) 727 (8.0) 1,525 (8.3) 10.2  
Primary 2,559 (34.7) 2,974 (27.3) 2,788 (30.5) 2,745 (30.0) 5,522 (30.3) 6.9  
Secondary 3,275 (44.4) 4,739 (43.5) 3,997 (43.8) 4,017 (43.9) 8,014 (43.8) 4.2  
University 1,071 (14.5) 2,138 (19.6) 1,553 (17.0) 1,656 (18.1) 3,209 (17.6) 4.1  
Prior cardiac disease       1.9 
MI 1,960 (18.8) 1,229 (9.8) 2,245 (19.2) 944 (8.1) 3,189 (13.8) 13.9  
Angina 1,233 (11.8) 1,976 (15.7) 2,392 (20.5) 817 (7.0) 3,209 (13.9) 13.9  
Heart failure 507 (4.9) 320 (2.5) 662 (5.7) 165 (1.4) 827(3.6) 3.6  
Atrial fibrillation 497 (4.8) 188 (1.5) 498 (4.3) 187 (1.6) 685 (3.0) 3.0  
Any of the above 2,904 (27.8) 2,890 (22.9) 4,115 (35.3) 1,679 (14.8) 5,794 (25.2) 9.3  
Prior COPD/other CLD 683 (6.6) 352 (2.8) 637 (5.5) 398 (3.5) 1,035 (4.5) 13.7 1.9 
BMI, kg/m2, mean (SD) 27.7 (4.4) 24.6 (3.4) 26.2 (4.3) 25.7 (4.0) 25.9 (4.1) 4.1 11.3 
<20 kg/m2 156 (1.7) 806 (6.8) 448 (4.2) 514 (5.0) 962 (4.6) 11.4  
Ejection fraction at admission       7.3 
Normal ≥40% 8,676 (89.4) 11,099 (92.0) 10,181 (92.7) 9,594 (88.9) 19,775 (90.9) 4.6  
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Moderately reduced 30–39% 787 (8.1) 714 (5.9) 550 (5.0) 951 (8.8) 1,501 (6.9) 12.9  Severely reduced <30% 239 (2.5) 250 (2.1) 247 (2.2) 242 (2.2) 489 (2.2) 20.9 
Diagnosis       0.0 
NSTE-ACS 5,624 (53.2) 6,306 (48.8) 11,930 (100) 0 11,930 (50.8) 5.9  
STEMI 4,943 (46.8) 6,616 (51.2) 0 11,559 (100) 11,559 (49.2) 5.0  
Killip class at event       22.2 
I 8,296 (87.4) 6,591 (75.0) 6,173 (82.9) 8,714 (80.4) 14,887 (81.4) 4.6  
II 834 (8.8) 1,393 (15.9) 841 (11.3) 1,386 (12.8) 2,227 (12.2) 9.4  
III or IV 367 (3.9) 802 (9.1) 431 (4.8) 738 (6.8) 1,169 (6.4) 14.5  
Interventions during admission       0.5 
None 2,975 (28.2) 3,407 (26.6) 4,616 (39.0) 1,766 (15.3) 6,382 (27.3) 9.8  
PCI 6,898 (65.4) 8,757 (68.3) 6,909 (58.3) 8,746 (75.9) 15,655 (67.0) 3.8  
CABG 268 (2.5) 107 (0.8) 285 (2.4) 90 (0.8) 375 (1.6) 3.5  
Reperfusion 7,339 (69.5) 9,316 (72.7) 6,963 (58.8) 9,692 (84.1) 16,655 (71.3) 3.9  
Any of the above 7,580 (71.8) 9,406 (73.4) 7,230 (61.0) 9,756 (84.7) 16,986 (72.7) 3.8  
Serum creatinine, mg/dL, mean (SD) 1.05 (0.5) 1.10 (0.6) 1.10 (0.6) 1.06 (0.5) 1.08 (0.58) – 4.6 
Blood glucose, mg/dL, mean (SD) 143.7 (79.9) 139.6 (69.0) 135.4 (76.5) 147.7 (71.0) 141.4 (74.1)  12.0 
Haemoglobin, g/dL, mean (SD) 14.1 (2.0) 13.7 (2.5) 13.7 (2.4) 14.0 (2.1) 13.9 (2.3) – 5.3 
<11 g/dL 434 (4.4) 975 (7.9) 825 (7.3) 584 (5.3) 1,409 (6.3) 16.0  
11–12.9 g/dL 1,788 (18.1) 3,201 (25.9) 2,777 (24.6) 2,212 (20.2) 4,989 (22.4) 7.4  
≥13 g/dL 7,654 (77.5) 8,186 (66.2) 7,692 (68.1) 8,148 (74.5) 15,840 (71.2) 3.9  
In-hospital cardiac complications       0.8 
MI or recurrent ischemia 600 (5.7) 590 (4.6) 592 (5.0) 598 (5.0) 1,190 (5.1) 8.5  
Cardiogenic shock 109 (1.0) 312 (2.4) 65 (0.5) 356 (3.0) 421 (1.8) 10.7  
Heart failure 616 (5.8) 663 (5.1) 513 (4.3) 766 (6.4) 1,279 (5.5) 15.9  
Any arrhythmia 1,013 (9.6) 587 (4.6) 567 (4.8) 1,033 (8.7) 1,600 (6.8) 10.1  
Any of the above 1,943 (18.5) 1,863 (14.5) 1,550 (13.0) 2,256 (19.6) 3,806 (16.3) 10.4  
Simple EQ-5D score at discharge       2.0 
0 4,774 (46.3) 8,156 (64.1) 6,437 (55.0) 6,493 (57.4) 12,930 (56.1) 3.5  
1 2,206 (21.4) 1,533 (12.1) 1,916 (16.4) 1,823 (16.1) 3,739 (16.2) 16.2  
≥2 3,333 (32.2) 3,028 (23.8) 3,358 (28.7) 3,003 (26.5) 6,361 (27.6) 27.6  
On diuretics at discharge 1,966 (18.7) 1,694 (13.2) 2,020 (17.0) 1,640 (14.3) 3,660 (15.7) 12.6 0.5 
On aldosterone inhibitor at discharge 898 (8.5) 1,019 (7.9) 733 (6.2) 1,184 (10.3) 1,917 (8.2) 12.7 0.5 
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BMI, body mass index; CABG: coronary artery bypass graft; CLD, chronic lung disease; COPD: chronic obstructive pulmonary disease; EQ-5D, EuroQol; MI, myocardial 
infarction; NSTE-ACS; non-ST-elevation acute coronary syndrome; PCI: percutaneous coronary intervention; SD: standard deviation; STEMI: ST-segment elevation myocardial 
infarction. 
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Table 2. Multivariate analysis of 2-year mortality: final model for all patients 
Variable Risk coefficient HR 95% CI P 
Age (per 10 years) 0.42 1.52 1.44‒1.61 <.00001 
Ejection fractiona     
<40% 0.57 1.77 1.50‒2.09 
<.00001 
<30% 0.87 2.40 1.93‒2.98 
No coronary revascularisation or thrombolysis 0.58 1.79 1.58‒2.02 <.00001 
EQ-5D score at discharge     
1 0.22 1.24 1.16‒1.33  
<.00001 
≥2 0.43 1.54 1.35‒1.77 
Previous cardiac disease 0.34 1.41 1.24‒1.59 <.00001 
Prior COPD/other CLD 0.45 1.57 1.31‒1.88 <.00001 
Serum creatinine (per log unit if ≥1.2 mg/dL)a,b 0.66 1.94 1.63‒2.32 <.00001 
Blood glucose (per 100 mg/dL if ≥140 mg/dL)a,c 0.19 1.21 1.12‒1.32 <.00001 
Haemoglobina     
<13 g/dL 0.24 1.27 1.10‒1.45  
<11 g/dL 0.60 1.82 1.52‒2.18 <.00001 
On diuretics at discharge 0.30 1.35 1.17‒1.55 <.0001 
On aldosterone inhibitor at discharge 0.29 1.34 1.14‒1.58 .0005 
Male sex 0.28 1.32 1.15‒1.51 <.0001 
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Education     
No formal 0.00 1.00 –  
Primary –0.14 0.87 0.80‒0.93 .0002 
Secondary –0.29 0.75 0.65‒0.87  
University –0.43 0.65 0.52‒0.82  
In-hospital cardiac complications 0.22 1.25 1.09‒1.42 .0009 
BMI <20 kg/m2 0.36 1.43 1.16‒1.77 .0009 
Diagnosis of STEMI 0.20 1.22 1.07‒1.38 .002 
Killip class     
I 0.00 1.00 ‒  
II 0.18 1.19 1.01‒1.41 .004 
 
III–IV 0.32 1.38 1.14‒1.67 
Country/region     
China 0.00 1.00 ‒ 
<.00001 
Hong Kong, Singapore, South Korea –0.50 0.60 0.42‒0.87 
India 0.10 1.05 0.83‒1.32 
Malaysia, Thailand, Vietnam 0.05 1.10 0.90‒1.35 
Eastern Europe 0.21 1.24 1.01‒1.51 
Latin America 0.36 1.44 1.19‒1.73 
Western Europe (North) –0.33 0.72 0.59‒0.88 
Western Europe (South) –0.11 0.89 0.72‒1.10 
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BMI, body mass index; CI, confidence interval; CLD, chronic lung disease; COPD, chronic obstructive pulmonary disease; HR, hazard ratio; STEMI, ST-segment elevation 
myocardial infarction. 
Risk coefficient = ln(HR) 
aduring admission.  
bexample, for creatinine 3.26 mg/dL [log(3.26) = log(1.2) + 1] HR is 1.98 compared with creatinine ≤1.2mg/dL. 
cexample, for glucose 240 mg/dL HR is 1.21 compared with glucose ≤140 mg/dL.  
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Table 3. Multivariate analysis of 2-year mortality: final model separated by 
diagnosis  
 NSTE-ACS STEMI 
Variable HR 95% CI HR 95% CI 
Age (per 10 years) 1.55 1.43–1.67 1.51 1.39–1.64 
Ejection fractiona     
<40% 1.89 1.50–2.38 1.65 1.30–2.10 
<30% 2.28 1.69–3.08 2.72 1.96–3.77 
No coronary revascularisation or thrombolysis 1.83 1.56–2.16 1.72 1.42–2.07 
EQ-5D score at discharge     
1 1.19 1.09–1.30 1.30 1.18–1.44 
≥2 1.42 1.18–1.70 1.69 1.39–2.06 
Previous cardiac disease 1.32 1.12–1.55 1.54 1.26–1.86 
Prior COPD/other CLD 1.80 1.44–2.25 1.23 0.89–1.70 
Serum creatinine (per log unit if ≥1.2 mg/dL)a,b 1.98 1.58–2.48 1.89 1.40–2.55 
Blood glucose (per 100 mg/dL if ≥140 mg/dL)a,c 1.26 1.12–1.42 1.16 1.02–1.31 
Haemoglobina     
<11 g/dL 1.88 1.48–2.39 1.79 1.36–2.34 
<13 g/dL 1.35 1.12–1.63 1.18 0.96–1.46 
On diuretics at discharge 1.30 1.08–1.57 1.36 1.09–1.68 
On aldosterone inhibitor at discharge 1.49 1.18–1.88 1.23 0.97–1.57 
Male sex 1.39 1.17–1.66 1.23 1.00–1.52 
Education     
No formal 1.00 – 1.00 – 
Primary 0.85 0.77–0.94 0.89 0.79–0.99 
Secondary 0.73 0.59–0.89 0.78 0.63–0.98 
University 0.62 0.46–0.84 0.70 0.50–0.97 
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In-hospital cardiac complications 1.27 1.06–1.53 1.23 1.02–1.49 
BMI <20 kg/m2 1.34 0.99–1.81 1.58 1.18–2.12 
Killip class     
I 1.00 – 1.00 – 
II 1.07 0.84–1.35 1.33 1.06–1.19 
III–IV 1.27 0.96–1.67 1.54 1.18–1.99 
Country/region     
China 1.00 – 1.00 – 
Hong Kong, Singapore, South Korea 0.77 0.49–1.21 0.43 0.23–0.79 
India 1.06 0.77–1.44 1.08 0.83–1.41 
Malaysia, Thailand, Vietnam 1.32 0.97–1.80 0.81 0.57–1.15 
Eastern Europe 1.47 1.12–1.92 1.02 0.75–1.38 
Latin America 1.59 1.22–2.06 1.29 0.99–1.70 
Western Europe (North) 0.84 0.64–1.09 0.58 0.41–0.82 
Western Europe (South) 1.05 0.80–1.39 0.73 0.52–1.01 
BMI, body mass index; CI, confidence interval; CLD, chronic lung disease; COPD, chronic obstructive pulmonary 
disease; HR, hazard ratio; NSTE-ACS: non-ST-elevation acute coronary syndrome; STEMI, ST-segment 
elevation myocardial infarction. 
aduring admission. 
bexample, for creatinine 3.26 mg/dL [log(3.26) = log(1.2) + 1] HR is 1.98 compared with creatinine ≤1.2mg/dL. 
cexample, glucose 240 mg/dL HR is 1.21 compared with glucose ≤140 mg/dL.  
For every variable, comparison of HR values for STEMI and NSTE-ACS respectively, revealed no evidence of a 
statistical interaction; P>.05 for all interaction tests performed. 
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Figure 1. Mortality hazard ratios for each variable in the predictive model 
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BMI, body mass index; CABG, coronary artery bypass graft; CI, confidence interval; CLD, chronic lung disease; 
COPD, chronic obstructive pulmonary disease; EQ-5D, EuroQol; LV, left ventricular; NSTE-ACS, non-ST-
elevation acute coronary syndrome; PCI, percutaneous coronary intervention; STEMI, ST segment elevation 
myocardial infarction. 
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Figure 2. (A) Risk score distribution and predicted mortality risk, (B) 
Cumulative mortality and (C), Risk discrimination and model goodness-of-fit 
A 
 
B 
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Panels B and C’; risk groups 1–4 correspond to quintiles 1–4, with the fifth quintile subdivided into 2 deciles (risk 
groups 5 and 6). 
 
